Sanuwave Completes Modular PMA For Diabetic Foot Ulcer Treatment
This article was originally published in The Gray Sheet
Executive Summary
Sanuwave Health completed a modular PMA application for its dermaPACE diabetic foot ulcer treatment with the submission of pivotal trial data, announced July 6.
You may also be interested in...
Sanuwave On Track To Submit dermaPACE PMA By June 30
Sanuwave Health says it is on track to wrap up a PMA submission by the end of June for its dermaPACE wound care device, which treats chronic diabetic foot ulcers with high-energy acoustic pressure waves.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.